Navigation Links
ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood
Date:11/8/2007

d cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.

This press release includes only summary information and does not purport to be comprehensive. The projections, forecast and estimates of ExonHit Therapeutics which may be contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such projections, forecast and estimates involve known and unknown risks and uncertainties, as described at Section 4.2 "Facteurs de risque" (Risk Factors) of the Document de Base available on ExonHit Therapeutics' website (http://www.exonhit.com), that may cause actual results, performance or events to differ materially from those anticipated in the summary information.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contacts:

ExonHit Therapeutics

Bruno Toc
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
3. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Carrington Completes $8 Million Financing
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. New Brunswick Scientific Completes Merger Transaction with Eppendorf
8. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
9. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Companys Partner Completes Trial Production of a New Antiviral Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Research and Markets  has announced the addition of ... Business Report" report to their offering. ... Cells (SOFCs) in US$ Thousands. The report provides separate comprehensive ... Europe , Asia-Pacific , and ... the period 2012 through 2020. Market data and analytics are ...
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
(Date:8/19/2014)... Aug. 19, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... today that its novel C. difficile ... th Interscience Conference on Antimicrobial Agents and ... D.C. Synthetic Biologics, Senior ...
(Date:8/18/2014)... (PRWEB) August 19, 2014 2014 ... Industryā€¯ is a professional and in-depth research report ... basic Linalool information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4
... 2011 VIGILAIR Systems, an industry leader ... a newly published, and first of its kind hospital ... Acquired Infections (HAI) with the application of VIGILAIR® air ... The published article , Effect of enhanced ...
... Calif., April 8, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... announced public offering of 6,700,000 shares of its common stock ...  The public offering is expected to close on or around ... Capital Inc. is the sole book-running manager in this offering ...
... 7, 2011 Cephalon, Inc. (NASDAQ: CEPH ... filed with the Securities and Exchange Commission (SEC) that ... Valeant Pharmaceuticals International, Inc.,s proposals to remove and replace ... consent solicitation cards to Valeant.  On April 5, 2011, ...
Cached Biology Technology:Newly Published Study Shows Dramatic Reduction in Hospital Acquired Infections 2Sangamo Announces Pricing of Public Offering of Common Stock 2Sangamo Announces Pricing of Public Offering of Common Stock 3Cephalon Recommends Shareholders Reject Valeant Nominees 2Cephalon Recommends Shareholders Reject Valeant Nominees 3Cephalon Recommends Shareholders Reject Valeant Nominees 4Cephalon Recommends Shareholders Reject Valeant Nominees 5
(Date:8/20/2014)... past few years, Virginia Tech,s Wu Feng has built ... from the "Computing in the Cloud" program, and synergistically ... million award from the Air Force on "big computing" ... and the National Institutes of Health on "big data" ... the "parallel computing" aspects from each grant, he was ...
(Date:8/20/2014)... University researchers have developed methods for electronically manipulating the ... signals moths use to control those muscles. The work ... or "biobots," for use in emergency response. , "In ... can control the movement of moths for use in ... Alper Bozkurt, an assistant professor of electrical and computer ...
(Date:8/19/2014)... 19, 2014 To improve students, chances of ... the University of Houston (UH) implemented a comprehensive ... at risk for failure. , Through a ... (THECB), the Department of Biology and Biochemistry embarked ... taking "General Biology" for non-majors and "Introductory Biology" ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Research paves way for development of cyborg moth 'biobots' 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... reside in designated Special Areas of Conservation throughout the ... risk from pile driving. The frequency range of pile ... find food and avoid predators. This has the potential ... breed successfully. Lactating females and young calves might be ...
... Special Areas of Conservation throughout the UK, including Dorset, ... driving. The frequency range of pile driving noise could ... avoid predators. This has the potential to affect their ... females and young calves might be particularly vulnerable ...
... fruits and vegetables to their daily diets. Now, UC Davis ... the kinds of cellular activity that leads to the development ... "We've known for a long time that it's the flavonoids ... known exactly how. Now, at least in the case of ...
Cached Biology News:South Pacific plant may be missing link in evolution of flowering plants 2Dolphins at risk 2UC Davis researchers reveal apples' protective ways 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
...
...
Biology Products: